Thus, a cohort study to explore whether improving serum HMGB1 levels through pharmacological targeting will affect the prognosis of DKD would be a better option to reflect the true relationship between HMGB1 and DKD and evaluate its predictive value. Here, HMGB1 is linked to diabetic kidney disease.